Ex-FDA cancer chief Richard Pazdur calls for restructuring CDER, more disease-specific centers like OCE and greater adcomm transparency.
Richard Pazdur, who spent more than two decades leading the FDA’s cancer drug reviews, said the agency has a “golden opportunity” to restructure after being …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Rick Pazdur on the FDA: “We've had a lot of destruction here, and it doesn't mean that we have to just go back and say, well,…
Rick Pazdur on the FDA: “We've had a lot of destruction here, and it doesn't mean that we have to just go back and say, well,…
Three acting FDA leaders at BIO pitch rare disease framework and 2,200-hire rebuilding plan as agency works to restore trust…
As leadership changes create more instability at the FDA, here’s what one former agency official thinks it will take to keep…
Hundreds of biopharma leaders say Dr Richard Pazdur has the necessary qualities to lead the FDA amid a crisis of confidence.
Experts clash over significance of agency's reversals on certain rare disease drugs
